Roche Wins 'Complimentary' Diagnostic Approval With Bladder Cancer Immune Therapy
This article was originally published in The Gray Sheet
Executive Summary
FDA approved Roche's Ventana PD-L1 assay to help identify patients more likely to respond to its Tecentriq drug for bladder cancer. It's approved as a helpful tool, rather than required test, with the drug, but the assay is part of a growing class of diagnostics that are likely to play an important supporting role in a promising and high-growth branch of oncology.
You may also be interested in...
US Approvals Analysis: Stroke Device, IVDs Highlight October FDA Actions
A PFO-closure device was finally approved for stroke in October. Also during the month, important personalized medicine diagnostics approvals and a next-gen robotic system for stent procedures.
Roche's Oncology Drug Strategy Emphasizes Comprehensive Diagnostics
Executives emphasized the role of "comprehensive diagnostics" in its plan to establish a dominant position in immuno-oncology drugs at this years' American Society of Clinical Oncology annual meeting.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”